Skip to content
IM Injection Allopathic

Invega Sustenna 100 mg/prefilled syringe im injection

Generic: Paliperidone Palmitate

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength100 mg/prefilled syringe
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per im injection. Ask your pharmacist before you switch brands.

Paliperidone Palmitate 100 mg/prefilled syringe im injections

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Paliperidone Palmitate guide

Indications

Schizoaffective Disorder Paliperidone Palmitate is an atypical antipsychotic indicated for Treatment of schizophrenia in adults. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.

Dosage and administration

Schizophrenia: Initiation Dosing: Day 1-234 mg and Day 8-156 mg Monthly Maintenance Dose: 39-234 mg Maximum Monthly Dose: 234 mg Schizoaffective disorder: Initiation Dosing: Day 1-234 mg and Day 8-156 mg Monthly Maintenance Dose: 78-234 mg Maximum Monthly Dose: 234 mg Administered 5 weeks after the first injection. The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg). Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.

Side effects

The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.

Precautions and warnings

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack). Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring. QT Prolongation: Avoid use with drugs that also increase QT interval and in patients with risk factors for prolonged QT interval. Tardive Dyskinesia: Discontinue drug if clinically appropriate. Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain. Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope. Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Paliperidone Palmitate if clinically significant decline in WBC in the absence of other causative factors. Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. Potential for Cognitive and Motor Impairment: Use caution when operating machinery. Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.

Pregnancy and lactation

Limited data from published literature report the presence of paliperidone in human breast milk. There is no information on the effects on the breastfed infant or the effects on milk production

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250